Handelsavisen
prelaunch
Companies ›Healthcare ›NCEL.O
NC
NCEL.O — NASDAQ Biotechnology

Ncel.O

$3,26
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
15,6M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-114,5 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
699
Day range
$3,20–$3,57
Prev close
$3,45
Open
$3,34
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

NCEL.O is a biotechnology company operating within the Health Care sector, though specific product details and revenue sources are not disclosed in the available data.

Business. National Bank of Pakistan (NCEL.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target23,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
23,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
1 analysts · indicative
Ownership→
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability→
-114,5 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NCEL.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NCEL.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    National Bank of Pakistan (NCEL.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    (a) Capital structure and liquidity: The company holds $2.2 million in cash and equivalents against total liabilities of $4.2 million, resulting in a debt-to-equity ratio of 0.0. Total equity stands at $7.2 million, while the market capitalization is approximately $16.8 million, implying a price-to-book ratio of 2.32. Operating cash flow is negative at -$2.8 million, indicating a cash-burn profile typical of early-stage biotechnology firms. The current ratio is not explicitly provided, but the absence of debt suggests low immediate solvency risk despite negative operating flows.

    (b) Profitability and returns: The company reports a net loss of $8.3 million and an operating loss of $2.6 million. Return on equity is -114.5%, and return on assets is -72.5%, reflecting significant value destruction relative to the capital base. These metrics are consistent with pre-revenue or early-revenue biotechnology companies that prioritize research and development over profitability. No cohort median data is available to benchmark these returns against peers.

    Key takeaways
    • The company is unprofitable with a net loss of $8.3 million and negative operating cash flow of -$2.8 million.
    • Balance sheet is debt-free with $2.2 million in cash, resulting in a 0.0 debt-to-equity ratio.
    • Analysts maintain a bullish outlook with a mean price target of $23.00, significantly above the current market price of $3.51.
    • Classification confidence is low (0.20), indicating potential ambiguity in the company’s sector or business model.
    • No historical financial trends or segment data are available to assess growth or revenue concentration.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2025-05-16
    FY 2025 · Full-year highlights

    Operating income +84,1% YoY; Net income +83,7% YoY.

    Revenue—
    Operating income-$1.9M+84,1 % YoY
    Net income-$2.0M+83,7 % YoY
    Free cash flow-$4.1M+66,6 % YoY
    EPS—
    Operating cash flow-$4.3M+55,9 % YoY
    Financials
    Income statement
    Revenue—
    Gross profit—
    Operating income-$1.9M
    Net income-$2.0M
    Balance sheet
    Total assets$2.2M
    Total liabilities$826.8k
    Total equity$1.4M
    Cash & equivalents$1.7M
    Long-term debt$0.00
    Cash flow
    Operating cash flow-$4.3M
    CapEx-$3.9k
    Free cash flow-$4.1M
    SBC—
    Highlights
    • ▍Operating income +84,1% YoY
    • ▍Net income +83,7% YoY
    • ▍Free cash flow +66,6% YoY

    Valuation FY

    Market price
    $3,26
    Market cap
    $16.8M
    Enterprise valueⓘ
    $14.6M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    2.3x
    P / Tangible bookⓘ
    2.3x
    Tangible book
    $7.2M
    Net cashⓘ
    $2.2M
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    -72.5%
    ROEⓘ
    -1.1%
    Cash conversionⓘ
    33.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures

    Supply chain

    Vendors → NCEL ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSNCELNCELNcel.O2 entitiesEledon PharmaceuticalsBiotechnology & Medical USAmylyx PharmaceuticalsPharmaceuticalsUS
    2 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$23,00 · Median $23,00
    Low $23,00High $23,00
    Operating income · consensus-6,0M USD

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$23,00
    Mean$23,00
    Median$23,00
    High$23,00
    Spot$3,26
    +605.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-114,5 %Bottom quartile
    D/E0,00Above median
    Cash Conv0,33Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 190 908 sh2 transactions2 insiders
    • Revel MichelDirector, CSO and Director, 10% owner · Warrant (right to buy) → Common Shares, par value CHF 0.05 per shareAcquired 76 363 @ $3,02purchase · 2026-04-27
    • Samuel OlivierDirector · Warrant (right to buy) → Common Shares, par value CHF 0.05 per shareAcquired 114 545 @ $3,02purchase · 2026-04-27

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    Source documents
    • NEWCELX LTD. Market data — financials · 2026-07-28
    • reconciler_enqueue (reconciler) on NCEL.O · 2026-07-28
    • NewcelX AG Market data — analyst estimates · 2026-07-28
    • NewcelX AG Market data — ESG · 2026-07-28
    • NCEL.O HA canonical relationships · 2026-07-28

    Ownership & reference

    Top holders

    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying2 buys · 0 sellsnet $375K2 insiders · last 365d
    • Samuel OlivierDirector · Common Shares, par value CHF 0.05 per shareBought 81 818 @ $2,75$225K · 2026-04-27
    • Revel MichelDirector, CSO and Director, 10% owner · Common Shares, par value CHF 0.05 per shareBought 54 545 @ $2,75$150K · 2026-04-27

    Short positioning

    56.5Kshares short+0.9% vs prior
    1days to cover
    25.7%short of daily vol
    11.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NCEL.OCanonical
    NASDAQ · USD

    Intel & risk

    What changed

    no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)

    • Narrative— → —medium
    • Business summary— → —medium
    • Conclusion— → —medium
    • Key takeaways— → —medium
    vs prior analysis 60 days ago
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    NCELELDN.OAMLX.OBiotechnology
    This companySectorPartners

    Evidence & claims

    From filings & derived data
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 13.5%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 190.7%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 1,167.4%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -52.9%Derived (calculated)
    • Return on equity (FY 2025-12-31): -114.5%Derived (calculated)
    • Return on assets (FY 2025-12-31): -72.5%Derived (calculated)
    • Current ratio (FY 2025-12-31): 0.76xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.58xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 33.3%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 238.6%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -11.1%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -11.1%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -15.3%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -159.5%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -24.0%Derived (calculated)
    • Cash & equivalents (annual): USD 2.2MSEC XBRL filing
    • Shareholders' equity (annual): USD 7.25MSEC XBRL filing
    • Total assets (annual): USD 11.45MSEC XBRL filing
    • Net income (annual): USD -8.3MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES 2SEC XBRL filing
    • Operating cash flow (annual): USD -2.77MSEC XBRL filing
    • Current assets (annual): USD 3.18MSEC XBRL filing
    • Total liabilities (annual): USD 4.2MSEC XBRL filing
    • Capex (annual): USD 8KSEC XBRL filing
    Showing 24 of 47 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-05FILINGCURRENT REPORT →
    2026-04-29FILINGANNUAL REPORT →
    2026-04-27 00:00 UTCINSIDER4 insider transactions — 2026-04 · net buy $375k 2 derivative
    2026-04-27INSIDERSamuel Olivier bought 81.8k sh Common Shares, par value CHF 0.05 per share — Director ~$225k
    2026-04-27INSIDERRevel Michel bought 54.5k sh Common Shares, par value CHF 0.05 per share — Director, CSO and Director, 10% owner ~$150k
    2026-04-27INSIDERRevel Michel acquired 76.4k sh Warrant (right to buy) — Director, CSO and Director, 10% owner
    2026-04-27INSIDERSamuel Olivier acquired 114.5k sh Warrant (right to buy) — Director
    2025-05-16 16:03 UTCEARNINGSAnnual results — FY 2025 Net USD -2.0M
    2024-05-15 16:02 UTCEARNINGSAnnual results — FY 2024 Net USD -12.2M
    2023-05-05 16:37 UTCEARNINGSAnnual results — FY 2023 Net USD -16.5M
    2022-03-24 17:09 UTCEARNINGSAnnual results — FY 2022 Net USD -11.9M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage